Imax

IMAX · NYSE

$52.44+$0.77 (+1.49%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $51.67

IMAX analyst rating

BuyConsensus of 12 analysts over the last 12 months. 83% rate it a buy.

Strong buy0
Buy10
Hold2
Underperform0
Sell0

12-month price target · 16 analysts

Average $58.32 (+11.2% upside)

Low: $45.45
Now: $52.44
High: $70.35

Upgrades and downgrades

The latest rating actions, newest first

IMAX analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Wells Fargo	Oct 15, 2026	Maintains	Equal-Weight	$45.00 → $55.00	67%
Wedbush	Oct 14, 2026	Maintains	Outperform	$54.00 → $60.00	56%
Rosenblatt	Oct 14, 2026	Maintains	Buy	$65.00	57%
B. Riley Securities	Oct 8, 2026	Maintains	Buy	$61.00 → $64.00	59%
StoneX	Oct 7, 2026	Maintains	Buy	$60.00 → $65.00	54%
Morgan Stanley	Sep 24, 2026	Initiates	Overweight	$63.00	0%
Rosenblatt	Sep 9, 2026	Maintains	Buy	$60.00 → $65.00	57%
Goldman Sachs	Sep 4, 2026	Maintains	Neutral	$42.00 → $50.00	59%
Roth Capital	Sep 3, 2026	Maintains	Buy	$50.00 → $60.00	69%
Macquarie	Sep 2, 2026	Maintains	Outperform	$50.00 → $55.00	40%

The case for and against

Updated Oct 21, 2026

Bull case

Imax is viewed positively because its record $712 million global box office in 3Q, led by The Odyssey’s nearly $400 million contribution, shows powerful demand for premium IMAX presentations and strong operating leverage. The company’s expected Q3 revenue of $161 million, EBITDA of $84 million to $91 million, and EPS of $0.98, alongside a 9.4% share of domestic box office versus a 5% average in 2025 and 4% in 2023–2024, indicate that its branded platform is gaining share and converting attendance into earnings efficiently. Its expanding 2026–2027 slate, deep studio relationships, and ability to pivot programming across local language, alternative content, and major tentpoles support further network growth, margin expansion, and durable cash generation.

Bear case

Imax is exposed to multiple fundamental weaknesses that pressure its long-term earnings quality, including weak macro conditions, uncertain box-office demand, and secular shifts in how movies are watched. Its dependence on blockbuster tent-pole films, commercial exhibitors, and the success of IMAX DMR content makes revenue vulnerable if audience demand softens or exhibitors reduce purchases, leases, or revenue-sharing activity. Added risks from China regulation, competitive encroachment, technology adoption uncertainty, IP protection issues, and variable quarterly operating results further support a negative outlook.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.